Evelo Biosciences, Inc.
Hedge Funds Holdings
Last updated:
Evelo Biosciences, Inc.‘s stocks are currently a part of 23 hedge funds’ portfolios, which represents 34.25% of the total amount of its stocks outstanding. This makes up a total of 29.85M shares of Evelo Biosciences, Inc.. Compared to the previous quarter, the number fell by -65.70% or -57.18M shares fewer. As for the holding position changes, 26.09% (6) of current hedge fund investors increased the number of shares held, 26.09% (6) of current holders sold a part of the shares held, and 13.04% (3) closed the holdings completely. 3 hedge funds are new holders of Evelo Biosciences, Inc. stock in Q1 2023, it is 13.04% of total holders.
Hedge funds holding Evelo Biosciences (Q2 2018 – Q1 2023)
| Q2 2018 | 41 |
|---|---|
| Q3 2018 | 37 |
| Q4 2018 | 41 |
| Q1 2019 | 41 |
| Q2 2019 | 39 |
| Q3 2019 | 42 |
| Q4 2019 | 42 |
| Q1 2020 | 40 |
| Q2 2020 | 46 |
| Q3 2020 | 47 |
| Q4 2020 | 49 |
| Q1 2021 | 62 |
| Q2 2021 | 65 |
| Q3 2021 | 61 |
| Q4 2021 | 64 |
| Q1 2022 | 65 |
| Q2 2022 | 41 |
| Q3 2022 | 37 |
| Q4 2022 | 41 |
| Q1 2023 | 23 |
Hedge funds changes in Evelo Biosciences positions (Q2 2018 – Q1 2023)
| Q2 2018 | 41 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q3 2018 | 3 | 18 | 7 | 7 | 2 |
| Q4 2018 | 7 | 21 | 6 | 3 | 4 |
| Q1 2019 | 5 | 17 | 11 | 5 | 3 |
| Q2 2019 | 2 | 19 | 8 | 2 | 8 |
| Q3 2019 | 5 | 15 | 10 | 2 | 10 |
| Q4 2019 | 2 | 15 | 12 | 2 | 11 |
| Q1 2020 | 2 | 13 | 15 | 4 | 6 |
| Q2 2020 | 8 | 23 | 8 | 2 | 5 |
| Q3 2020 | 6 | 20 | 11 | 5 | 5 |
| Q4 2020 | 10 | 23 | 8 | 8 | 0 |
| Q1 2021 | 15 | 31 | 12 | 2 | 2 |
| Q2 2021 | 12 | 27 | 16 | 8 | 2 |
| Q3 2021 | 8 | 23 | 15 | 11 | 4 |
| Q4 2021 | 12 | 28 | 10 | 8 | 6 |
| Q1 2022 | 10 | 18 | 24 | 9 | 4 |
| Q2 2022 | 9 | 9 | 19 | 29 | -25 |
| Q3 2022 | 6 | 9 | 13 | 11 | -2 |
| Q4 2022 | 8 | 17 | 7 | 7 | 2 |
| Q1 2023 | 3 | 6 | 6 | 3 | 5 |
Hedge funds changes in Evelo Biosciences stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 0 | 0 |
|---|---|---|
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 0 | 0 |
| Q4 2020 | 0 | 0 |
| Q1 2021 | 0 | 168,000 |
| Q2 2021 | 607,000 | 424,000 |
| Q3 2021 | 4,866,000 | 6,531,000 |
| Q4 2021 | 2,542,000 | 417,000 |
| Q1 2022 | 49,000 | 221,000 |
| Q2 2022 | 210,000 | 51,000 |
| Q3 2022 | 207,000 | 30,000 |
| Q4 2022 | 161 | 322 |
| Q1 2023 | 0 | 0 |